This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CRISP2 / Cysteine-rich secretory protein 2 · IHC design guide
Design Immunohistochemistry for CRISP2
Plan CRISP2 IHC-P in human testis using the catalog antibody, starting at 10 μg/mL (datasheet: IHC-P). Use nuclear staining in elongated or late spermatids as the tissue reference (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CRISP2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear in elongated or late spermatids (HPA tissue IHC) | |
| Staining pattern | Nuclear staining in elongated or late spermatids (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Testis | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Secreted protein; RNA and protein sites may differ (HPA tissue IHC) | |
| Regulation | Testis-enriched RNA (HPA RNA) | |
| Isoform / epitope | 2 isoforms; epitope differences unreported (UniProt) |
Section 1
Recommended CRISP2 IHC & IF Protocols
Review the catalog antibody protocol alongside the published boar testis IHC protocol (PMC8119884).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A10681); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-CRISP2, 10 μg/mL (datasheet A10681) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CRISP2-positive staining in elongated or late spermatids of testis (HPA tissue IHC: High). HPA tissue profile: Selective nuclear expression in testis. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page antigen-retrieval rule); the boar testis study also used citrate at 95 °C (PMC8119884).
Section 2
What Is the Expected CRISP2 Staining Pattern?
CRISP2 is secreted and has no transmembrane segment (UniProt P16562 topology). In tissue IHC, the expected observed pattern is selective nuclear staining in elongated or late spermatids in testis (HPA: tissue IHC profile). HPA rates staining in these cells High and assigns the tissue result Enhanced reliability, while noting medium agreement with RNA and disregarded presumed off-target staining (HPA: tissue IHC).
| Strong nuclear staining in elongated or late spermatids, with little staining elsewhere in the section. | This matches HPA's selective nuclear testis profile and High staining in those cells (HPA: tissue IHC). Score the identified cell population and compartment together; overall section darkness alone cannot establish the expected pattern. |
| Cytoplasmic or widespread extracellular color dominates, without the expected spermatid nuclear pattern. | The compartment disagrees with the observed tissue IHC profile (HPA: selective nuclear expression). Secreted annotation does not establish where chromogenic signal should appear in this section (UniProt P16562; HPA: tissue IHC). Check morphology and controls before assigning specificity. |
| Cells outside the expected spermatid population stain prominently. | Treat this as possible cross-reactivity or endogenous detection activity, especially in an HPA-listed negative cell type (HPA: tissue IHC negatives). A no-primary control helps identify detection-system color; it does not prove that antibody-dependent staining is specific (general IHC practice). |
| Diffuse color obscures boundaries between stained and unstained cells. | The expected selective pattern cannot be scored reliably against diffuse background (HPA: tissue IHC profile). Review the no-primary control, blocking, washes and chromogen development as general IHC troubleshooting steps; background alone does not identify which step failed. |
| No staining appears in morphologically identifiable elongated or late spermatids. | This is an uninformative negative result if those cells are present: HPA reports High staining there (HPA: testis tissue IHC). Check section identity and cell preservation, then assess retrieval and detection controls as general IHC practice before interpreting absence. |
💡Expected CRISP2 appearanceCall the IHC result positive when elongated or late spermatid nuclei show strong, selective staining in testis (HPA: High; selective nuclear profile); broad staining of unrelated cells or diffuse color is suspect until controls resolve it.
| Secreted protein and observed compartment | UniProt classifies CRISP2 as secreted, with no transmembrane segment (UniProt P16562 topology). HPA nevertheless observes selective nuclear tissue staining (HPA: tissue IHC). Use the observed IHC pattern for slide interpretation; the annotation alone cannot explain its nuclear signal. |
| Protein processing and antibody epitope | UniProt lists a signal peptide at residues 1–21 and a mature chain at 22–243 (UniProt P16562 processing). The supplied evidence gives no antibody epitope, so it cannot establish which processed form contributes to staining. |
| Isoforms and tissue scope | UniProt lists 2 isoforms and tissue specificity in testis and epididymis (UniProt P16562). HPA's supplied positive IHC observation is confined to testis spermatids (HPA: tissue IHC); these records do not establish isoform-specific staining or an epididymal IHC pattern. |
| Confidence in the tissue pattern | HPA lists antibody HPA031248 as IHC Enhanced and rates the tissue result Enhanced (HPA: antibody validation; tissue IHC). HPA also reports medium agreement with RNA and presumed off-target binding that it disregarded (HPA: tissue IHC); assess unexpected staining with controls. |
| Can IF/ICC confirm the nuclear pattern? | HPA lists CRISP2 as secreted but supplies no main ICC-IF location or cell-line images (HPA: subcellular). Thus this payload cannot establish an IF/ICC staining pattern. Evaluate IF/ICC on its own evidence; the nuclear call here comes from tissue IHC. |
| Situation | Likely cause | Next action |
|---|---|---|
| The testis section has no apparent positive cells. | The expected elongated or late spermatids may be absent or unrecognizable, or the assay may have failed (HPA: High staining in those cells; general IHC practice). | Confirm that the relevant cells are present on the counterstained section. Then check the staining run's positive and detection controls before changing retrieval or antibody conditions. |
| Spermatids stain, but the color is mainly outside their nuclei. | The distribution does not match HPA's selective nuclear tissue pattern (HPA: tissue IHC); secreted topology does not validate a different IHC compartment (UniProt P16562). | Recheck cell identification and nuclear boundaries on the counterstain. Compare with a validated positive section and inspect the no-primary control before calling the alternate distribution specific. |
| HPA-listed negative cell types show prominent color. | HPA reports no detection in the listed cells, so antibody cross-reactivity or endogenous detection activity merits investigation (HPA: tissue IHC negatives; general IHC practice). | Check a no-primary control for detection-system color. If that control is clear, reassess antibody-dependent staining with appropriate controls; do not infer that every cell in the listed tissues must be negative. |
| Background is diffuse across the section. | Nonselective reagent deposition or detection activity may obscure the expected nuclear contrast (general IHC practice; HPA: selective nuclear profile). | Review blocking, washes, detection reagents and chromogen development. Compare positive and no-primary controls, then score CRISP2 only where cell identity and nuclear localization remain clear. |
| Staining is weaker than expected in identifiable late spermatids. | HPA reports High staining in elongated or late spermatids, but the supplied sources do not identify a CRISP2-specific cause of weak signal (HPA: tissue IHC). | Verify slide quality and run controls, then review antigen retrieval and antibody dilution using the chosen assay's validated instructions (general IHC practice). Do not claim CRISP2-specific fixation sensitivity from these sources. |
Experiment evidence
IHC & IF images showing CRISP2 staining
A10681 · IHCImmunohistochemistry of CRISP2 in human testis tissue with CRISP2 antibody at 10 μg/mL.
A10681 · IFImmunofluorescence of CRISP in human testis tissue with CRISP antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000124490-CRISP2/tissue/cerebral+cortex#imid_7749984
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000124490-CRISP2/tissue/colon#imid_7749126
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000124490-CRISP2/tissue/liver#imid_7749127
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000124490-CRISP2/tissue/kidney#imid_7749128
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CRISP2 IHC & IF
🧪Run testis first: elongated or late spermatids should stain strongly (HPA: High in elongated or late spermatids). Use adipose tissue as a negative control (HPA: Not detected in adipocytes); on the testis slide, assess other cells for background staining without assuming every other cell type is CRISP2-negative.
Positive control tissue: Testis (Elongated or late spermatids, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for CRISP2; derive a cell-line control from the positive tissue's cell type (Elongated or late spermatids) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and clonality (standard IHC practice). Where available, use CRISP2 knockout material or an appropriate immunizing-peptide block to test specificity (standard IHC practice).
Check endogenous peroxidase activity on testis sections for chromogenic detection; check autofluorescence if using IF (standard IHC/IF practice).
Check endogenous peroxidase activity on testis sections for chromogenic detection; check autofluorescence if using IF (standard IHC/IF practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A10681 testis IHC caption does not state a fixative (caption: fixative not stated). Antigen-retrieval dependence is unreported; optimize retrieval on paraffin testis sections (application: IHC on paraffin sections). The supplied evidence does not establish whether frozen sections or IF/ICC are easier; no ICC-IF image cell lines are listed, and testis autofluorescence should be assessed if IF is attempted (HPA: no ICC-IF image cell lines; standard IF practice).
HPA tissue IHC evidence for CRISP2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Secreted protein, tissue location of RNA and protein is expected to differ. Presumed off target binding observed and disregarded.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Elongated or late spermatids | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CRISP2 IHC Tips
Use testis staining patterns and independent controls to assess CRISP2 IHC; the available tissue evidence does not establish every processing condition (HPA; selected caption).
How should I adjust retrieval when CRISP2 staining is weak or uneven?
Start with citrate pH 6.0 heat-induced epitope retrieval at 95–98 °C for 20 min (page retrieval setting). Compare adjacent testis sections with identical antibody and detection conditions before changing retrieval, using late spermatids as the expected positive population (HPA: high in elongated or late spermatids; standard IHC practice). If staining remains weak, test a second retrieval condition on matched sections as a fallback and record any gain in background or tissue damage (standard IHC practice). The selected tissue caption reports CRISP2 staining at 10 µg/mL, but gives no retrieval method, so it cannot validate that setting for SKU A10681 (selected caption: A10681).
Could fixation explain weak CRISP2 staining in my paraffin sections?
CRISP2-specific fixation sensitivity is unknown: the selected human testis caption does not state its fixative, and no target-specific fixation comparison is supplied (selected caption: A10681). Record fixative, fixation duration, section age, and retrieval conditions for each specimen before attributing differences in staining to CRISP2 biology (standard IHC practice). Compare matched sections processed together and inspect morphology as well as signal, because damaged or unevenly processed tissue can confound chromogenic scoring (standard IHC practice). Do not infer a preferred fixative from the testis staining pattern or from CRISP2 being secreted and lacking a transmembrane segment (HPA: testis profile; UniProt P16562 topology).
Which staining compartment should count as a plausible CRISP2 signal?
Prioritise elongated or late spermatids when assessing positive testis sections; HPA reports high staining there and describes a selective nuclear testis pattern (HPA: tissue IHC). Interpret compartment cautiously because CRISP2 is annotated as secreted, has a signal peptide at residues 1–21, and has no transmembrane segment (UniProt P16562). Compare the nuclear and extranuclear patterns across intact seminiferous structures, using morphology and matched controls rather than compartment alone to call a cell positive (standard IHC practice). A strong signal in unrelated cell populations should prompt review of specificity, especially since presumed off-target binding was observed and disregarded in the HPA assessment (HPA: reliability description).
How can epitope placement affect CRISP2 staining across specimens?
CRISP2 has 2 listed isoforms, but the supplied evidence does not identify the catalog antibody’s epitope or establish which isoforms it detects (UniProt P16562; selected caption: A10681). The precursor has a signal peptide at residues 1–21 and a reported mature chain at 22–243, so epitope mapping matters when evaluating processed protein (UniProt P16562). Check the antibody’s documented immunogen or epitope before interpreting differences between specimens as isoform changes, and retain matched positive testis controls during optimization (standard IHC practice; HPA: testis enrichment). If epitope information remains unavailable, report the result as CRISP2 immunoreactivity without assigning an isoform or processing state (standard IHC practice).
How would I assess CRISP2 in a multiplex IF experiment?
Use a marker that identifies elongated or late spermatids alongside CRISP2, since those are the testis cells with high reported tissue staining (HPA: tissue IHC). Choose spectrally separated fluorophores after checking testis autofluorescence in an unstained section, and include single-stain controls to assess channel bleed-through (standard IF practice). Select permeabilisation based on the antibody epitope’s accessibility: an intracellular epitope requires access across the cell membrane, while the supplied evidence does not locate this antibody’s epitope (standard IF practice; selected caption: A10681). Treat any IF pattern as a separate validation result because the supplied catalog image documents tissue IHC, and HPA lists no cell-line ICC/IF images (selected caption: A10681; HPA: subcellular).
What should I check when testis sections show diffuse brown staining?
Compare a no-primary control with the CRISP2-stained section to identify signal arising from the chromogenic detection system rather than primary-antibody binding (standard IHC practice). Include a peroxidase-blocking step when using peroxidase and DAB, and inspect unstained tissue for native pigment that could resemble reaction product (standard IHC practice). Titrate the antibody and detection exposure on matched sections while preserving the late-spermatid signal expected in testis (standard IHC practice; HPA: high in elongated or late spermatids). Be especially cautious with widespread staining outside that population: HPA describes presumed off-target binding and only medium consistency between staining and RNA expression (HPA: reliability description).
How should I score CRISP2 staining across testis sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define elongated or late spermatids as the primary scoring population before reviewing slides, because HPA reports high CRISP2 staining in those cells (HPA: tissue IHC). Record the percentage of positive cells and an intensity-based H-score using a fixed threshold, then normalise to the number of evaluable cells in that population (standard IHC practice). If counting positive cells per mm², also report the sampled tissue area and restrict comparisons to comparable seminiferous regions (standard IHC practice). Score nuclear and extranuclear signal separately, since HPA describes selective nuclear expression while UniProt annotates CRISP2 as secreted, and keep processing and imaging conditions consistent (HPA: tissue IHC; UniProt P16562; standard IHC practice).
How can I distinguish credible CRISP2 staining from artefact?
A credible result should be reproducible in intact elongated or late spermatids, the population with high reported staining in testis (HPA: tissue IHC; standard IHC practice). Review unexpected compartment staining against HPA’s selective nuclear pattern and UniProt’s secreted annotation; neither source alone establishes that every other pattern is artefactual (HPA: tissue IHC; UniProt P16562). Exclude section edges, necrotic areas, and signal reproduced by a no-primary control before calling additional cells positive (standard IHC practice). Check peroxidase controls if brown product appears broadly, and weigh unexpected cell staining cautiously because the HPA assessment notes presumed off-target binding (standard IHC practice; HPA: reliability description).
Boster reagents
Best CRISP2 / Cysteine-rich secretory protein 2 IHC Antibodies
The catalog lists one human-reactive anti-CRISP2 antibody for IHC-P and IF (catalog: A10681 applications/reactivity), with IHC and IF images of human testis tissue (A10681 image captions).
Real IHC data
Anti-CRISP2 Antibody
Cat # A10681
A10681 will render with its human testis IHC image at 10 μg/mL (A10681 IHC caption). It also lists IF and has a human testis IF image at 20 μg/mL (catalog: A10681 applications; A10681 IF caption).
Which to pick: For paraffin-section IHC, choose A10681 because IHC-P and human reactivity are listed (catalog: A10681 applications/reactivity); its own IHC caption shows human testis tissue, but does not report the fixative (A10681 IHC caption). For IF, A10681 has a human testis image (A10681 IF caption); ICC-specific validation is unreported (catalog: A10681 applications and image captions). No listed SKU establishes cross-species reactivity: A10681 lists human only, has a rabbit host, and has no clone designation (catalog: A10681 reactivity/host/clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P16562 (CRIS2_HUMAN, Cysteine-rich secretory protein 2).
- Human Protein Atlas. CRISP2 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. CRISP2 subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. CRISP2 antibody validation summary (1 antibodies).
- Investigation Into the Relationship Between Sperm Cysteine-Rich Secretory Protein 2 (CRISP2) and Sperm Fertilizing Ability and Fertility of Boars. Frontiers in veterinary science 2021 — PMC8119884.
- Discovery and validation of novel biomarkers for detection of cervical cancer. Cancer medicine 2021 — PMC7957177.
- PubMed PMID:2613236 — UniProt-cited evidence.
- PubMed PMID:8665901 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CRISP2 (Cysteine-rich secretory protein 2). Expected localisation Nuclear in elongated or late spermatids (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10681 at 10 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Testis (Elongated or late spermatids); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A10681); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-CRISP2, 10 μg/mL (datasheet A10681); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Secreted protein; RNA and protein sites may differ (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope differences unreported (UniProt); Regulation: Testis-enriched RNA (HPA RNA). Evidence: UniProt P16562, HPA tissue IHC · Enhanced, HPA ICC-IF · Secreted, Datasheet A10681, PMC8119884. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CRISP2/immunohistochemistry-ihc-guide.